Abstract Churg–Strauss syndrome (CSS), alternatively known as eosinophilic
granulomatosis with polyangiitis (EGPA), was first described in 1951 by Churg and Strauss …

Background Eosinophilic granulomatosis with polyangiitis is an eosinophilic vasculitis.
Mepolizumab, an anti–interleukin-5 monoclonal antibody, reduces blood eosinophil counts …

Heart involvement in primary systemic vasculitides is important to recognize, because it has
been linked to increased mortality and requires prompt diagnosis and treatment. Almost all …

Eosinophilia is an important indicator of various neoplastic and nonneoplastic conditions.
Depending on the underlying disease and mechanisms, eosinophil infiltration can lead to …

Eosinophils, a constitutive component of the columnar-lined gastrointestinal tract, play an
essential role in allergic responses and parasitic infections. The tissue density of these cells …

Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare, small vessel, necrotizing
vasculitis. The disease is mainly characterized by hypereosinophilia and asthma with …

Mepolizumab is an anti-interleukin-5 (IL-5) humanized monoclonal antibody that binds to
free IL-5. It induces bone marrow eosinophil maturation arrest and decreases eosinophil …

Human eosinophils have characteristic morphologic features, including a bilobed nucleus
and cytoplasmic granules filled with cytotoxic and immunoregulatory proteins that are …

Recent advances have shown impressive results by anti-interleukin 1 (IL-1) agents in
refractory idiopathic recurrent pericarditis. Purpose of Review We critically discuss the …

Systemic vasculitis are heterogeneous, complex and disabling disorders. Following the
previous annual reviews of this series, this paper gives a brief overview on current …